

POST-TEST

Recent Developments in the Management of Relapsed/Refractory Multiple Myeloma from ASH 2025: BCMA-Targeted Therapy and Investigational Agents — Microlearning Activity 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate median progression-free survival for patients with relapsed/refractory (R/R) multiple myeloma (MM) receiving belantamab mafodotin/pomalidomide/dexamethasone in the Phase III DREAMM-8 study?
 - a. 12 months
 - b. 20 months
 - c. 33 months**
 - d. 50 months
2. Which of the following drug descriptions best reflects the mechanism of action of KLN-1010?
 - a. A BCMA-targeting antibody-drug conjugate
 - b. A BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy
 - c. A modified lentiviral vector generating anti-BCMA CAR T cells in vivo**
 - d. I'm not sure
3. Approximately what proportion of patients with MM are alive and free of disease progression at 5 years after receiving cilta-cel (ciltacabtagene autoleucel) in the CARTITUDE-1 study?
 - a. 0%
 - b. 5%
 - c. 15%
 - d. 33%**
 - e. 50%
4. The RedirecTT-1 study evaluated which combination of agents for patients with R/R MM?
 - a. Belantamab mafodotin/talquetamab
 - b. Teclistamab/talquetamab**
 - c. Belantamab mafodotin/daratumumab
 - d. Elranatamab/talquetamab